Roche's oncology and diagnostics dominance continues to support a wide moat rating.
At the annual meeting of the American Association for Cancer Research (AACR), clinical data is emerging that is reinforcing Merck’s leading position in the largest immuno-oncology area of first-line non-small cell lung cancer (NSCLC), but we don’t expect any major changes to our fair value estimates based on the data and continue to view key immuno-oncology players Merck, Bristol, and Roche as undervalued. Additionally, the impressive clinical data at AACR from both Bristol and Merck in the unme...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.